(Q33182379)

23 July 2017

1 reference

title

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation (English)

1 reference

23 July 2017

Gelderblom H

1

1 reference

23 July 2017

Verweij J

series ordinal

2

1 reference

23 July 2017

Nooter K

series ordinal

3

1 reference

23 July 2017

Sparreboom A

series ordinal

4

1 reference

23 July 2017

1 September 2001

1 reference

European Journal of Cancer

23 July 2017

1 reference

23 July 2017

37

1 reference

23 July 2017

13

1 reference

23 July 2017

1590-1598

1 reference

Patient preferences for oral versus intravenous palliative chemotherapy

23 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Hypersensitivity reactions from taxol

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Adverse reactions to intravenous anaesthetic induction agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Complement-mediated reactions to diazepam with Cremophor as solvent (Stesolid MR).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Histamine release in dogs by Cremophor El® and its derivatives: Oxethylated oleic acid is the most effective constituent

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Cardiac disturbances during the administration of taxol

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance: the causative role of improper dissolution of Cremophor EL

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Anaphylaxis to intravenous cyclosporine and tolerance to oral cyclosporine: case report and review

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Unusual serum lipoprotein abnormality induced by the vehicle of miconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Interaction of cremophor EL with human plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

The alteration of plasma lipoproteins by cremophor EL

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Effects of Cremophor EL on distribution of Taxol to serum lipoproteins.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Effects of Taxol on blood cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

The polyoxyethylene castor oil Cremophor EL modifies multidrug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Reversal of multidrug resistance by surfactants

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Comparison of cyclosporin A, verapamil, PSC-833 and cremophor EL as enhancing agents of VP-16 in murine lymphoid leukemias

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Cremophor EL reversed multidrug resistance in vitro but not in tumor-bearing mouse models

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Clinical relevance of P-glycoprotein expression in haematological malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Is Cremophor EL, solvent for paclitaxel, cytotoxic?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

The cytotoxic activity of Taxol in primary cultures of tumour cells from patients is partly mediated by Cremophor EL.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Differential activity of Cremophor EL and paclitaxel in patients' tumor cells and human carcinoma cell lines in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Polyunsaturated fatty acid-induced cytotoxicity against tumor cells and its relationship to lipid peroxidation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Oncolytic effects of fatty acids in mice and rats

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol) in human tumor cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Linearized colorimetric assay for cremophor EL: application to pharmacokinetics after 1-hour paclitaxel infusions.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Titrimetric determination of Cremophor EL in aqueous solutions and biofluids: part 2: ruggedness of the method with respect to biofluids

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol) and carboplatin in non-small cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Problems in therapeutic drug monitoring: free drug level monitoring.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Sequences of taxol and cisplatin: a phase I and pharmacologic study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Differential alteration of cisplatin cytotoxicity and myelotoxicity by the paclitaxel vehicle cremophor EL.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Haematopoietic radioprotection by Cremophor EL: a polyethoxylated castor oil.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

Role of formulation vehicles in taxane pharmacology

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900171-X

7 January 2021

10.1016/S0959-8049(01)00171-X

Identifiers

DOI

1 reference

23 July 2017

1 reference